Vir Biotechnology (VIR) Free Cash Flow (2018 - 2026)

Vir Biotechnology has disclosed Free Cash Flow across 9 years of filings, most recently posting -$132.8 million for Q1 2026.

• Free Cash Flow for Q1 2026 came in at -$132.8 million, down 66.5% year-over-year; the trailing twelve-month figure through Mar 2026 was -$449.6 million (down 6.52% YoY), and the FY2025 annual result was -$396.6 million, up 12.57% from the prior year.
• Free Cash Flow came in at -$132.8 million for Q1 2026 at Vir Biotechnology, down from -$26.2 million in the prior quarter.
• In the past five years, Free Cash Flow ranged from a high of $939.5 million in Q2 2022 to a low of -$398.7 million in Q2 2023.
• The 5-year median for Free Cash Flow is -$109.5 million (2023), against an average of -$11.1 million.
• Across the five-year window, Free Cash Flow jumped 694.22% in 2022 and sank 585.38% in 2023, its largest moves.
• Vir Biotechnology's Free Cash Flow stood at $22.6 million in 2022, then tumbled by 585.38% to -$109.5 million in 2023, then advanced by 18.12% to -$89.6 million in 2024, then soared by 70.74% to -$26.2 million in 2025, then tumbled by 406.31% to -$132.8 million in 2026.
• The last three Free Cash Flow figures came in at -$132.8 million (Q1 2026), -$26.2 million (Q4 2025), and -$167.9 million (Q3 2025), per Business Quant data.